News
Gordon Research Conference for Fragile X and Autism disorders
Purposeful is thrilled to announce her participation at the Gordon Research Conference for Fragile X and Autism disorders, 15-20/5/2022, Lucca, Italy.
Tech Tour South East Europe
Purposeful participates at the Tech Tour South East Europe.
Collaboration with PHRF
We are very glad to announce the commence of our collaboration with the Pitt Hopkins Research Foundation!
Orphan Designation Fragile X Syndrome
The EC decided the designation of Purposeful’s medicinal product, containing codergocrine mesilate, oxitriptan as an orphan medicinal product for the indication: treatment of fragile X syndrome (EU/3/22/2586).
Purposeful at the AI Industry Connect Talks
Purposeful at the AI Industry Connect Talks on Wed 16/2/2022 at 14:00.
Purposeful on the 1st International Conference on Rare Diseases and Paediatric Research
Purposeful on the 1st International Conference on Rare Diseases and Paediatric Research, on 18 & 19 of November 2021!
Fragile X webinar, 18/10/2021, online via zoom
Join a 1-hour webinar for ongoing research in FXS and information on clinical trials now recruiting.
Single Blind Study in Adult Males With Fragile X Syndrome
Single Blind Study of Ergoloid Mesylates, 5-HTP and the Combination in Adult Males With Fragile X Syndrome, now published in Clinicaltrials.gov.
Purposeful at Findacure 2021
Purposeful participates at Findacure annual drug repurposing conference on May 16, 2021.